162 related articles for article (PubMed ID: 29607927)
1. Noncovalent Strategy with Cell-Penetrating Peptides to Facilitate the Brain Delivery of Insulin through the Blood-Brain Barrier.
Kamei N; Yamaoka A; Fukuyama Y; Itokazu R; Takeda-Morishita M
Biol Pharm Bull; 2018; 41(4):546-554. PubMed ID: 29607927
[TBL] [Abstract][Full Text] [Related]
2. Mechanistic study of the uptake/permeation of cell-penetrating peptides across a caco-2 monolayer and their stimulatory effect on epithelial insulin transport.
Kamei N; Onuki Y; Takayama K; Takeda-Morishita M
J Pharm Sci; 2013 Nov; 102(11):3998-4008. PubMed ID: 23963728
[TBL] [Abstract][Full Text] [Related]
3. Exploration of the Key Factors for Optimizing the in Vivo Oral Delivery of Insulin by Using a Noncovalent Strategy with Cell-Penetrating Peptides.
Kamei N; Shigei C; Hasegawa R; Takeda-Morishita M
Biol Pharm Bull; 2018; 41(2):239-246. PubMed ID: 29386483
[TBL] [Abstract][Full Text] [Related]
4. Brain delivery of insulin boosted by intranasal coadministration with cell-penetrating peptides.
Kamei N; Takeda-Morishita M
J Control Release; 2015 Jan; 197():105-10. PubMed ID: 25445695
[TBL] [Abstract][Full Text] [Related]
5. [Nose-to-Brain Delivery of Peptide Drugs Enhanced by Coadministration of Cell-penetrating Peptides: Therapeutic Potential for Dementia].
Kamei N
Yakugaku Zasshi; 2017; 137(10):1247-1253. PubMed ID: 28966266
[TBL] [Abstract][Full Text] [Related]
6. Combination Strategy with Complexation Hydrogels and Cell-Penetrating Peptides for Oral Delivery of Insulin.
Fukuoka Y; Khafagy ES; Goto T; Kamei N; Takayama K; Peppas NA; Takeda-Morishita M
Biol Pharm Bull; 2018; 41(5):811-814. PubMed ID: 29709919
[TBL] [Abstract][Full Text] [Related]
7. Oligoarginine-modified biodegradable nanoparticles improve the intestinal absorption of insulin.
Liu X; Liu C; Zhang W; Xie C; Wei G; Lu W
Int J Pharm; 2013 May; 448(1):159-67. PubMed ID: 23538098
[TBL] [Abstract][Full Text] [Related]
8. Visualization and Quantitative Assessment of the Brain Distribution of Insulin through Nose-to-Brain Delivery Based on the Cell-Penetrating Peptide Noncovalent Strategy.
Kamei N; Shingaki T; Kanayama Y; Tanaka M; Zochi R; Hasegawa K; Watanabe Y; Takeda-Morishita M
Mol Pharm; 2016 Mar; 13(3):1004-11. PubMed ID: 26795701
[TBL] [Abstract][Full Text] [Related]
9. In vivo proof of concept of oral insulin delivery based on a co-administration strategy with the cell-penetrating peptide penetratin.
Nielsen EJ; Yoshida S; Kamei N; Iwamae R; Khafagy el-S; Olsen J; Rahbek UL; Pedersen BL; Takayama K; Takeda-Morishita M
J Control Release; 2014 Sep; 189():19-24. PubMed ID: 24973720
[TBL] [Abstract][Full Text] [Related]
10. Cell-penetrating peptide enhanced insulin buccal absorption.
Xu Y; Zhang X; Wang N; Pei X; Guo Y; Wang J; Barth S; Yu F; Lee SJ; He H; Yang VC
Int J Pharm; 2020 Jun; 584():119469. PubMed ID: 32470482
[TBL] [Abstract][Full Text] [Related]
11. Molecular imaging analysis of intestinal insulin absorption boosted by cell-penetrating peptides by using positron emission tomography.
Kamei N; Morishita M; Kanayama Y; Hasegawa K; Nishimura M; Hayashinaka E; Wada Y; Watanabe Y; Takayama K
J Control Release; 2010 Aug; 146(1):16-22. PubMed ID: 20457194
[TBL] [Abstract][Full Text] [Related]
12. Effect of cell-penetrating peptides on the nasal absorption of insulin.
Khafagy el-S; Morishita M; Isowa K; Imai J; Takayama K
J Control Release; 2009 Jan; 133(2):103-8. PubMed ID: 18930084
[TBL] [Abstract][Full Text] [Related]
13. PEG-PGA enveloped octaarginine-peptide nanocomplexes: An oral peptide delivery strategy.
Niu Z; Samaridou E; Jaumain E; Coëne J; Ullio G; Shrestha N; Garcia J; Durán-Lobato M; Tovar S; Santander-Ortega MJ; Lozano MV; Arroyo-Jimenez MM; Ramos-Membrive R; Peñuelas I; Mabondzo A; Préat V; Teixidó M; Giralt E; Alonso MJ
J Control Release; 2018 Apr; 276():125-139. PubMed ID: 29518466
[TBL] [Abstract][Full Text] [Related]
14. Accumulation of arginine-rich cell-penetrating peptides in tumors and the potential for anticancer drug delivery in vivo.
Nakase I; Konishi Y; Ueda M; Saji H; Futaki S
J Control Release; 2012 Apr; 159(2):181-8. PubMed ID: 22285548
[TBL] [Abstract][Full Text] [Related]
15. Penetratin-functionalized PEG-PLA nanoparticles for brain drug delivery.
Xia H; Gao X; Gu G; Liu Z; Hu Q; Tu Y; Song Q; Yao L; Pang Z; Jiang X; Chen J; Chen H
Int J Pharm; 2012 Oct; 436(1-2):840-50. PubMed ID: 22841849
[TBL] [Abstract][Full Text] [Related]
16. Dual-Modified Liposome for Targeted and Enhanced Gene Delivery into Mice Brain.
Dos Santos Rodrigues B; Lakkadwala S; Kanekiyo T; Singh J
J Pharmacol Exp Ther; 2020 Sep; 374(3):354-365. PubMed ID: 32561686
[TBL] [Abstract][Full Text] [Related]
17. Applicability and Limitations of Cell-Penetrating Peptides in Noncovalent Mucosal Drug or Carrier Delivery Systems.
Kamei N; Bech Nielsen EJ; Nakakubo T; Aoyama Y; Rahbek UL; Pedersen BL; Takeda-Morishita M
J Pharm Sci; 2016 Feb; 105(2):747-753. PubMed ID: 26869427
[TBL] [Abstract][Full Text] [Related]
18. One-month subchronic toxicity study of cell-penetrating peptides for insulin nasal delivery in rats.
Khafagy el-S; Kamei N; Nielsen EJ; Nishio R; Takeda-Morishita M
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):736-43. PubMed ID: 24060698
[TBL] [Abstract][Full Text] [Related]
19. Enhanced oral bioavailability of insulin using PLGA nanoparticles co-modified with cell-penetrating peptides and Engrailed secretion peptide (Sec).
Zhu S; Chen S; Gao Y; Guo F; Li F; Xie B; Zhou J; Zhong H
Drug Deliv; 2016 Jul; 23(6):1980-91. PubMed ID: 26181841
[TBL] [Abstract][Full Text] [Related]
20. The improved blood-brain barrier permeability of endomorphin-1 using the cell-penetrating peptide synB3 with three different linkages.
Liu H; Zhang W; Ma L; Fan L; Gao F; Ni J; Wang R
Int J Pharm; 2014 Dec; 476(1-2):1-8. PubMed ID: 25245547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
